1
|
Nair S, Lushington GH, Purushothaman M, Rubin B, Jupe E, Gattam S. Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling. BIOTECH 2025; 14:15. [PMID: 40227336 PMCID: PMC11940096 DOI: 10.3390/biotech14010015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2025] [Revised: 02/20/2025] [Accepted: 03/02/2025] [Indexed: 04/15/2025] Open
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that poses serious long-term patient burdens. (1) Background: SLE patient classification and care are often complicated by case heterogeneity (diverse variations in symptoms and severity). Large language models (LLMs) and generative artificial intelligence (genAI) may mitigate this challenge by profiling medical records to assess key medical criteria. (2) Methods: To demonstrate genAI-based profiling, ACR (American College of Rheumatology) 1997 SLE classification criteria were used to define medically relevant LLM prompts. Records from 78 previously studied patients (45 classified as having SLE; 33 indeterminate or negative) were computationally profiled, via five genAI replicate runs. (3) Results: GenAI determinations of the "Discoid Rash" and "Pleuritis or Pericarditis" classification criteria yielded perfect concurrence with clinical classification, while some factors such as "Immunologic Disorder" (56% accuracy) were statistically unreliable. Compared to clinical classification, our genAI approach achieved a 72% predictive success rate. (4) Conclusions: GenAI classifications may prove sufficiently predictive to aid medical professionals in evaluating SLE patients and structuring care strategies. For individual criteria, accuracy seems to correlate inversely with complexities in clinical determination, implying that improvements in AI patient profiling tools may emerge from continued advances in clinical classification efficacy.
Collapse
Affiliation(s)
| | - Gerald H. Lushington
- Progentec Diagnostics, Inc., 755 Research Pkwy, Oklahoma City, OK 73104, USA; (S.N.); (M.P.); (B.R.); (E.J.); (S.G.)
| | | | | | | | | |
Collapse
|
2
|
Bahareth E, Alibrahim I, Bassas R, AlSulami M, Aljuaid A, Bukhari A, Khojah I, Nashawi M, Mirza A, Khojah A. Knowledge and attitude of caregivers regarding sun exposure and protection in pediatric age in Western Region, Saudi Arabia. Sci Rep 2025; 15:6206. [PMID: 39979524 PMCID: PMC11842837 DOI: 10.1038/s41598-025-90577-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2024] [Accepted: 02/13/2025] [Indexed: 02/22/2025] Open
Abstract
Children's sun safety habits have been studied globally, but there is a significant research gap in the western region of Saudi Arabia. This study aimed to assess caregivers' knowledge and attitudes about sun safety for children and adolescents in the Western region of Saudi Arabia. We conducted a cross-sectional study through a validated online questionnaire directed to caregivers living in the Western region of Saudi Arabia. Using 50% and 75% as cutoff thresholds, individuals were divided into three knowledge levels: low (scores from 15 to 44), average (from 45 to 59), and high (from 60 to 75). The study included 940 caregivers (53% were mothers). The majority of caregivers (73%) demonstrated an average level of knowledge about sun protection, with notable misconceptions such as the belief that sun protection is unnecessary in winter. Most of the participants could accurately identify health risks associated with excessive sun exposure such as the risk of skin cancer. Binary logistic regression analysis revealed that having a child aged 1 year or younger was an independent predictor of higher knowledge levels regarding sun exposure and protection (OR = 1.27; 95% CI: 1.01-1.6). Sun protection practices were inconsistent; 28.7% of caregivers never used sunscreen themselves, 34.9% never used them for their children and 23% used it exclusively in the summer months. In conclusion, while most participants exhibited average knowledge about sunlight exposure and protection, only 23.1% of caregivers applied sunscreen regularly on their children.
Collapse
Affiliation(s)
- Elaf Bahareth
- College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
| | | | - Rayyan Bassas
- College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
| | - Maria AlSulami
- College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
| | | | - Ameera Bukhari
- College of Science, Taif University, Taif, 21944, Saudi Arabia
| | - Imad Khojah
- Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Mohammed Nashawi
- Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Aisha Mirza
- Makkah Maternity and Children Hospital, Mecca, Saudi Arabia
| | - Amer Khojah
- Department of Pediatrics, College of Medicine, Umm Al-Qura University, P.O.Box 715, Al Abdeyah, Mecca, 24381, Saudi Arabia.
| |
Collapse
|
3
|
Christian L, Manjrekar P, Henkels KM, Rapp CM, Annamraju R, Lohade RP, Singh S, Carpenter MA, Khan S, Kemp MG, Chen Y, Sahu RP, Travers JB. Evidence for the involvement of keratinocyte-derived microvesicle particles in the photosensitivity associated with xeroderma pigmentosum type A deficiency. Photochem Photobiol 2024; 100:1457-1466. [PMID: 38287748 PMCID: PMC11284252 DOI: 10.1111/php.13915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 01/16/2024] [Accepted: 01/16/2024] [Indexed: 01/31/2024]
Abstract
Photosensitivity can be due to numerous causes. The photosensitivity associated with deficiency of xeroderma pigmentosum type A (XPA) has been previously shown to be associated with excess levels of the lipid mediator platelet-activating factor (PAF) generated by the keratinocyte. As PAF has been reported to trigger the production of subcellular microvesicle particles (MVP) due to the enzyme acid sphingomyelinase (aSMase), the goal of these studies was to discern if PAF and aSMase could serve as therapeutic targets for the XPA deficiency photosensitivity. HaCaT keratinocytes lacking XPA generated greater levels of MVP in comparison to control cells. Mice deficient in XPA also generated enhanced MVP levels in skin and in plasma in response to UV radiation. Use of a genetic strategy with mice deficient in both XPA and PAF receptors revealed that these mice generated less MVP release as well as decreased skin erythema and cytokine release compared to XPA knockout mice alone. Finally, the aSMase inhibitor imipramine blocked UV-induced MVP release in HaCaT keratinocytes, as well as XPA knockout mice. These studies support the concept that the photosensitivity associated with XPA involves PAF- and aSMase-mediated MVP release and provides a potential pharmacologic target in treating this form of photosensitivity.
Collapse
Affiliation(s)
- Lea Christian
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Pranali Manjrekar
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Karen M. Henkels
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Christine M. Rapp
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Risha Annamraju
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Rushabh P. Lohade
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Shikshita Singh
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | | | - Saman Khan
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Michael G. Kemp
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
- The Dayton V.A. Medical Center, Dayton, OH
| | - Yanfang Chen
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Ravi P. Sahu
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
| | - Jeffrey B. Travers
- Department of Pharmacology & Toxicology, Wright State University, Dayton OH
- Department of Dermatology, Wright State University, Dayton OH
- The Dayton V.A. Medical Center, Dayton, OH
| |
Collapse
|
4
|
Hysa E, Gotelli E, Campitiello R, Paolino S, Pizzorni C, Casabella A, Sulli A, Smith V, Cutolo M. Vitamin D and Muscle Status in Inflammatory and Autoimmune Rheumatic Diseases: An Update. Nutrients 2024; 16:2329. [PMID: 39064771 PMCID: PMC11280097 DOI: 10.3390/nu16142329] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 07/16/2024] [Accepted: 07/18/2024] [Indexed: 07/28/2024] Open
Abstract
Background and Objectives: Vitamin D is a secosteroid hormone essential for calcium homeostasis and skeletal health, but established evidence highlights its significant roles also in muscle health and in the modulation of immune response. This review aims to explore the impact of impaired vitamin D status on outcomes of muscle function and involvement in inflammatory and autoimmune rheumatic diseases damaging the skeletal muscle efficiency both with direct immune-mediated mechanisms and indirect processes such as sarcopenia. Methods: A comprehensive literature search was conducted on PubMed and Medline using Medical Subject Headings (MeSH) terms: "vitamin D, muscle, rheumatic diseases." Additionally, conference abstracts from The European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR) (2020-2023) were reviewed, and reference lists of included papers were scanned. The review emphasizes the evidence published in the last five years, while also incorporating significant studies from earlier years, structured by the extent of evidence linking vitamin D to muscle health in the most commonly inflammatory and autoimmune rheumatic diseases encountered in clinical practice. Results: Observational studies indicate a high prevalence of vitamin D serum deficiency (mean serum concentrations < 10 ng/mL) or insufficiency (<30 ng/mL) in patients with idiopathic inflammatory myopathies (IIMs) and polymyalgia rheumatica, as well as other autoimmune connective tissue diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Of note, vitamin D insufficiency may be associated with reduced muscle strength (2 studies on RA, 2 in SLE and 1 in SSc), increased pain (1 study on SLE), fatigue (2 studies on SLE), and higher disease activity (3 studies on IIMs and 1 on SLE) although there is much heterogeneity in the quality of evidence and different associations for the different investigated diseases. Therefore, linked to the multilevel biological intervention exerted by vitamin D, several translational and clinical studies suggest that active metabolites of this secosteroid hormone, play a role both in reducing inflammation, but also in enhancing muscle regeneration, intra-cellular metabolism and mitochondrial function, although interventional studies are limited. Conclusions: Altered serum vitamin D status is commonly observed in inflammatory and autoimmune rheumatic diseases and seems to be associated with adverse muscle health outcomes. While maintaining adequate serum vitamin D concentrations may confer muscle-protective effects, further research is needed to confirm these findings and establish optimal supplementation strategies to obtain a safe and efficient serum threshold.
Collapse
Affiliation(s)
- Elvis Hysa
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- Department of Experimental Medicine (DIMES), University of Genoa, Via Leon Battista Alberti 2, 16132 Genoa, Italy
| | - Emanuele Gotelli
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
| | - Rosanna Campitiello
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| | - Sabrina Paolino
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| | - Carmen Pizzorni
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| | - Andrea Casabella
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| | - Alberto Sulli
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| | - Vanessa Smith
- Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium;
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium
- Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium
| | - Maurizio Cutolo
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy; (E.H.); (R.C.); (S.P.); (C.P.); (A.S.)
- IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;
| |
Collapse
|
5
|
Carrión-Barberà I, Triginer L, Tío L, Pérez-García C, Ribes A, Abad V, Pros A, Monfort J, Salman-Monte TC. Serum Advanced Glycation End Products and Their Soluble Receptor as New Biomarkers in Systemic Lupus Erythematosus. Biomedicines 2024; 12:610. [PMID: 38540223 PMCID: PMC10968350 DOI: 10.3390/biomedicines12030610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 02/28/2024] [Accepted: 03/05/2024] [Indexed: 11/11/2024] Open
Abstract
It has been postulated that advanced glycation end products (AGEs) and their soluble receptor (sRAGE) may play a relevant role as inducers in the chronic inflammatory pathway in various conditions, among them, in immune-mediated diseases such as systemic lupus erythematosus (SLE). However, previous studies show conflicting results about their association with SLE characteristics and their usefulness as disease biomarkers. We aimed to study the association of specific serum AGEs (pentosidine, Nξ-(carboxymethyl)lysine (CML), Nξ-(carboxyethyl)lysine (CEL)), sRAGE levels and AGEs (specific serum AGEs and skin AGEs) to sRAGE ratios with various disease parameters, in order to clarify their potential as new biomarkers in SLE and to study their relationship with cardiovascular disease (CVD). To this aim, serum pentosidine, CML, CEL and sRAGE were measured via ELISA, and skin AGEs levels were measured by skin autofluorescence. Correlations of pentosidine levels with demographic and clinical data, indexes of activity, accrual damage and patient-reported outcomes were analyzed through multiple linear regression models, while correlations of the rest of the AGEs, sRAGE and AGE to sRAGE ratios (non-normal) were analyzed using both an OLS regression model and a GML. All of the analyses were adjusted for confounders. A total of 119 SLE patients were recruited. Serum AGEs and sRAGEs were significantly associated with SLE activity indexes and/or demographic or disease characteristics: pentosidine with pulmonary manifestations; CML with anti-dsDNA antibodies, IL-6, disease duration and non-Caucasian ethnicities; CEL with anti-dsDNA antibodies, IL-6 and accumulated number of manifestations; and sRAGE with male gender, photosensitivity and being on specific immunosuppressants. These results suggest that the AGE-sRAGE axis may serve as a novel biomarker for managing and prognosticating this disease. Its correlation with certain antibodies, demographics and disease presentations may indicate a distinct clinical phenotype associated with varying levels of AGEs and/or sRAGE. The significance of specific AGE/sRAGE ratios, introduced in this study for the first time, warrants additional investigation in forthcoming research. Our study did not confirm the link between serum AGEs and CVD, which merits further exploration through studies designed for this specific purpose.
Collapse
Affiliation(s)
- Irene Carrión-Barberà
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Medicine Department, Medicine Faculty, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| | - Laura Triginer
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
| | - Laura Tío
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
| | - Carolina Pérez-García
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| | - Anna Ribes
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
| | - Victoria Abad
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| | - Ana Pros
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| | - Jordi Monfort
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| | - Tarek Carlos Salman-Monte
- Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain; (I.C.-B.)
- Hospital del Mar Research Institute, 08003 Barcelona, Spain
- Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, 08003 Barcelona, Spain
| |
Collapse
|